AGC Biologics partners with Repair Biotechnologies to develop mRNA therapy for heart disease

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

AGC Biologics has announced a collaboration with Repair Biotechnologies to develop and manufacture a novel mRNA therapeutic designed to stabilise and shrink atherosclerotic plaques in major blood vessels. The initiative addresses atherosclerosis—whose plaque rupture leading to heart attack or stroke is cited as the cause of 27% of global mortality.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE